Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Chang

Showing results (331-340 of 386) with videos related to

Pageof 39
Sort By:
The Lancet. Oncology|October 31, 2024
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancementsJavier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, et al.
Neuro-Oncology|June 9, 2026
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directionsKarisa C Schreck, Macarena I de la Fuente, Mary Jane Lim Fat, et al.
Neuro-Oncology|January 2, 2024
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect groupPhilipp Karschnia, Antonio Dono, Jacob S Young, et al.
Neuro-Oncology|August 12, 2022
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect groupPhilipp Karschnia, Jacob S Young, Antonio Dono, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2017
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i>Tali Mazor, Charles Chesnelong, Aleksandr Pankov, et al.
Neuro-Oncology|June 5, 2013
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesisKyle M Walsh, Terri Rice, Paul A Decker, et al.
Neuro-Oncology Advances|November 3, 2022
<i>TERT</i> promotor status does not add prognostic information in <i>IDH</i>-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO <i>resect</i> groupPhilipp Karschnia, Jacob S Young, Antonio Dono, et al.
Pageof 39

Showing results (331-340 of 386) with videos related to

Sort By:
Pageof 39
The Lancet. Oncology|October 31, 2024
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancementsJavier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, et al.
Neuro-Oncology|June 9, 2026
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directionsKarisa C Schreck, Macarena I de la Fuente, Mary Jane Lim Fat, et al.
Neuro-Oncology|January 2, 2024
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect groupPhilipp Karschnia, Antonio Dono, Jacob S Young, et al.
Neuro-Oncology|August 12, 2022
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect groupPhilipp Karschnia, Jacob S Young, Antonio Dono, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2017
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i>Tali Mazor, Charles Chesnelong, Aleksandr Pankov, et al.
Neuro-Oncology|June 5, 2013
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesisKyle M Walsh, Terri Rice, Paul A Decker, et al.
Neuro-Oncology Advances|November 3, 2022
<i>TERT</i> promotor status does not add prognostic information in <i>IDH</i>-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO <i>resect</i> groupPhilipp Karschnia, Jacob S Young, Antonio Dono, et al.
Pageof 39